Riskpilot← Back to searchSign inGet full accessBioSource Europe AB
ABActiveOrg 5565894119Research and experimental development on natural sciences and engineering · NACE 7210Est. 20000 employees
Revenue 2025
SEK 0
EBITDA margin
—
-192% vs 2024
Equity ratio
70.6%
Financial strength
Net profit 2025
SEK 169K
+717% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -52K | -192% |
| Net profit | SEK 169K | +717% |
| Total assets | SEK 4,2M | -5% |
| Equity | SEK 2,9M | -1% |
| Employees | 0 | — |
Legal name
BioSource Europe AB
Org number
5565894119
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6 april 2000
Share capital
SEK 200 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva konsultverksamhet inom hälso- och sjukvårdssektorn såsom exempelvis läkemedelsutveckling innefattande styrelsearbete samt även rekrytering och bemanning för sagda sektor.
Address
Phone
+4684115660
Email
elisabeth@biosource.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 150 | 388 | 31 | −0 | 0 |
| Staff expenses | −130 | −109 | −24 | −0 | — |
| EBITDA | 1 760 | 30 | −119 | −18 | −52 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 1 760 | 30 | −119 | −18 | −52 |
| Net financials | −98 | 93 | 133 | 76 | 37 |
| Profit before tax | 1 244 | 123 | 14 | 35 | 223 |
| Tax | −259 | −13 | −5 | −14 | −54 |
| Net profit | 985 | 109 | 9 | 21 | 169 |
| Item | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 5 139 | 4 563 | 4 572 | 4 392 | 4 155 |
| Equity | 3 240 | 3 149 | 2 954 | 2 975 | 2 934 |
| Long-term debt | — | — | — | — | — |
| Short-term debt | 558 | 72 | 276 | 52 | 93 |
| Total debt | 558 | 72 | 276 | 52 | 93 |
EBITDA margin
-5158000.0%
This company
15.8%
Market median
-32645670% vs market
20222025
Equity ratio
70.6%
This company
38.2%
Market median
+85% vs market
20222025
Return on equity
5.7%
This company
18.4%
Market median
-69% vs market
20222025
Net profit margin
16869200.0%
This company
8.1%
Market median
+208261628% vs market
20222025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222025
Debt / equity
0.42×
This company
0.62×
Market median
+32% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-09-01 – 2023-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BioSource Europe AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Axel Lindner Olsson | Deputy Board Member | 0 companies |
| Edith Olga Elisabeth Lindner | Board of Directors | 0 companies |